Trial Profile

Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darapladib (Primary)
Indications Coronary artery disease
Focus Therapeutic Use
Acronyms AIM-III

Most Recent Events

02 Nov 2017 Results (n=54) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record. (NCT01067339)
22 Sep 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com